The new entity focuses on the discovery, design and development of RLTs. Credit: PeopleImages.com – Yuri A/Shutterstock.

Sanofi and Orano Group subsidiary Orano Med have announced a partnership to enhance the development of next-generation radioligand therapies (RLTs) for rare cancers.

The companies plan to invest in a new entity, operating under the brand Orano Med, which focuses on the discovery, design and development of RLTs based on lead-212 (212Pb) alpha-emitting isotopes.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Sanofi’s €300m ($325m) equity investment will give it a 16% stake in the new entity valued at €1.9bn.

This investment is expected to strengthen Orano Med further and allow the company to expedite its pipeline development, leveraging its lead-212-based therapies discovery and development capabilities.

The strategic partnership follows Sanofi’s recent licensing agreement with Orano Med and RadioMedix, focusing on the advanced project AlphaMedix.

See Also:

Sanofi CEO Paul Hudson stated: “This collaboration is part of a broader effort to strengthen our ties within the scientific community, both in France and globally, to advance the development of cutting-edge treatments for patients.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

As a potent alpha-emitting radioisotope, 212Pb is at the forefront of targeted alpha-emitter therapy, which combines biological vectors and alpha-emitting radioisotopes to target and destroy cancer cells.

Orano Group CEO Nicolas Maes said: “By applying our expertise in nuclear materials to fields like targeted alpha therapies, we are demonstrating that nuclear technology can have a positive societal impact, not just for energy and climate, but also for human health.

“This innovation reflects Orano’s commitment to exploring new opportunities and taking bold steps to address some of the world’s most pressing challenges.”

The collaboration is contingent on standard regulatory approvals.

Both Sanofi and Orano Med are part of the Paris Saclay cancer cluster and are committed to supporting the France 2030 plan’s objectives in oncology innovation.